Online inquiry

IVTScrip™ mRNA-Human ADGRL2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK12546MR)

This product GTTS-WK12546MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ADGRL2 protein. This product can be used in Meiotic prophase fetal germ cell-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Human
RefSeq NM_001297704.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 23266
UniProt ID O95490
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ADGRL2, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK12546MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK23848MR IVTScrip™ mRNA-Human ARL6IP4, (Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ARL6IP4
GTTS-WK24768MR IVTScrip™ mRNA-Human ARPC3, (Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ARPC3
GTTS-WK24901MR IVTScrip™ mRNA-Human APCDD1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA APCDD1
GTTS-WK20237MR IVTScrip™ mRNA-Human alpha-SMA, (Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA alpha-SMA
GTTS-WK22585MR IVTScrip™ mRNA-Human ARHGAP18, (Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARHGAP18
GTTS-WK13389MR IVTScrip™ mRNA-Human ADAM12, (Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADAM12
GTTS-WK10957MR IVTScrip™ mRNA-Human ACTA2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ACTA2
GTTS-WK22399MR IVTScrip™ mRNA-Human ASB7, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ASB7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW